UHealth - University of Miami Health System

E-mail a Friend


Macarena I. De La Fuente, M.D.

General Information

Macarena I. De La Fuente, M.D.

Contact

  • Fax: 305-243-7081

Specialties

  • Neurology (Psychiatry & Neurology)

Languages

English, Spanish

Clinical Areas

University of Miami Brain Tumor Initiative

Primary brain tumors: Glioblastoma, Glioma, Ependymoma, Neurocytoma, Meningioma, Ganglioglioma.

Clinical trials in which Dr. de la Fuente is involved are listed below:

A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Investigator: Macarena De La Fuente
National Clinical Trials Identifier: NCT02152982
Phase: Phase II/III

Dendritic Cell Vaccine for Malignant Glioma And Glioblastoma Multiforme in Adult and Pediatric Subjects
Investigator: Macarena De La Fuente
National Clinical Trials Identifier: NCT01808820

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation AG 120-C-002
Investigator: Jonathan Trent
National Clinical Trials Identifier: NCT02073994
Phase I

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects with Advanced Solid Tumors, including Glioma, and with Angioimmunoblastic T-cell Lymphoma, that Harbor an IDH2 Mutation
Investigator: Breelyn Wilky
National Clinical Trials Identifier: NCT02273739
Phase: Phase I/II

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein peptide COMPLEX96 (HSPPC96) (nsc 725085, Alliance ind 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme
Investigator: Ricardo Komotar
National Clinical Trials Identifier: NCT01814813
Phase 2
 
RTOG 1205: Randomized Phase II Trial for Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Investigator: Fazilat Ishkanian
National Clinical Trials Identifier: NCT01730950
Phase 2
 
A Phase III Randomized Double Blind Placebo Controlled Study of Armodafonil (Nuvigil) To Reduce Cancer Related Fatigue in Patients With High Grade Glioma
Investigator: Deborah Heros
National Clinical Trials Identifier: NCT01781468
Phase 3
 
A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
Investigator: Fazilat Ishkanian
National Clinical Trials Identifier: NCT01372774
Phase 3

Roles

  • Assistant Professor

Research Interests

IDH mutant glioma, glioblastoma, meningioma, radiographic biomarker for IDH mutant glioma.

Education

M.D.
Universidad Nacional de La Plata
Residency
FLENI Institute
Neuro-oncology Fellowship
Memorial Sloan-Kettering Cancer Center

Biography

Dr. Macarena de la Fuente is a neuro-oncologist who specializes in the care of patients with primary brain tumors. She obtained her medical degree from Universidad Nacional de La Plata, Buenos Aires, Argentina in 2004, and subsequently completed a neurology residency at FLENI Institute, Buenos Aires, Argentina. Dr. de la Fuente obtained further subspecialty training in neuro oncology at the Memorial-Sloan Kettering Cancer Center, New York.

Dr. de la Fuente conducts clinical trials in an effort to develop innovative, more effective treatments for brain tumors in both the upfront and recurrent settings. Her research interest focuses on IDH-mutant gliomas, specifically investigating radiographic biomarkers for these tumors.

E-mail a Friend